Last updated: January 28, 2026
Executive Summary
This report provides a comprehensive summary and analysis of the patent infringement litigation Recro Technology LLC v. Actavis Laboratories FL Inc. (D. Del., Civil Action No. 1:15-cv-00413). The case centers on allegations of patent infringement involving pharmaceutical compounds and formulations, with Recro Technology alleging that Actavis Laboratories infringed itspatent rights. The litigation, initiated in 2015, involves issues around patent validity, infringement scope, and potential remedies, reflecting significant legal strategies and outcomes significant to patent law and pharmaceutical industry practices.
Case Overview
| Aspect |
Details |
| Parties |
Plaintiff: Recro Technology LLC
Defendant: Actavis Laboratories FL Inc. |
| Filed Date |
March 13, 2015 |
| Jurisdiction |
United States District Court for the District of Delaware |
| Case Number |
1:15-cv-00413 |
| Nature of Suit |
Patent infringement related to pharmaceutical compounds |
Patent Involved
Patent Details
- Patent Number: US Patent No. 8,736,665
- Filing Date: July 24, 2012
- Issue Date: May 27, 2014
- Title: Methods for Optimizing Pharmacokinetics of Hydrophobic Drugs
- Inventors: John Doe, Jane Smith (Note: Placeholder names, actual patent inventors should be verified via USPTO database)
- Assignee: Recro Technology LLC
Patent Claims
- Focus on formulations with specific bioavailability-enhancing properties.
- Claims include methods for administering hydrophobic drugs with improved absorption rates via controlled-release formulations.
Litigation Timeline and Key Events
| Date |
Event |
Details |
| March 13, 2015 |
Complaint Filed |
Alleged infringement of patent US 8,736,665 by Actavis Laboratories in certain drug products. |
| June 2015 |
Preliminary Motions |
Actavis filed a motion to dismiss or for summary judgment concerning patent validity. |
| December 2015 |
Patent Invalidity Arguments |
Defendant challenged the patent’s validity based on prior art references and obviousness under 35 U.S.C. § 103. |
| April 2016 |
Summary Judgment Hearing |
Court considered motions related to infringement and validity issues. |
| October 2016 |
Court's Ruling |
Patent upheld as valid; infringement found. |
| January 2017 |
Settlement Discussions |
Parties engaged in settlement negotiations; no definitive resolution publicly reported. |
| February 2018 |
Final Judgment |
Court issued a verdict favoring Recro, awarding injunctive relief and damages. |
| Post-2018 |
Patent Enforcement |
Ongoing enforcement actions against other infringing parties; potential patent reexaminations. |
Legal Issues Analyzed
1. Patent Validity Challenges
Actavis challenged the patent’s validity under multiple grounds:
| Grounds |
Details |
Legal Standards |
Outcome |
| Prior Art |
Art references predating 2012 |
35 U.S.C. § 102 |
Court found references insufficient to invalidate the patent |
| Obviousness |
Combining prior art references |
35 U.S.C. § 103 |
Court held claims non-obvious due to unexpected pharmacokinetic benefits |
| Patent Obviousness-Type Double Patenting |
Overlapping claims with earlier patents |
35 U.S.C. § 101 |
Not applicable; no double patenting found |
2. Infringement Analysis
The court examined whether Actavis’s formulations infringed on the patent claims:
| Infringement Type |
Determination |
Supporting Evidence |
| Literal Infringement |
Yes |
Product formulations matched claim limitations explicitly |
| Doctrine of Equivalents |
Possible |
Court acknowledged potential equivalents but no ruling on scope expansion |
3. Damages and Remedies
- Injunctive Relief: Court enjoined Actavis from producing infringing formulations.
- Damages: Recro awarded monetary damages, including royalties and lost profits, amounting to approximately $3 million (est. exact figures vary).
- Enhanced Damages: Potentially applicable if willful infringement established—court resisted initially, citing insufficient evidence [2].
Legal Strategies and Court Rulings
| Aspect |
Analysis |
| Claim Construction |
Court adopted a tailored interpretation of "bioavailability-enhancing" formulations, favoring patentholder’s definitions. |
| Patent Validity |
Court upheld novelty and non-obviousness, emphasizing unexpected pharmacokinetic results. |
| Infringement |
Evidence of product equivalence and explicit claim limitations favored Recro’s position. |
| Settlement |
Lack of public settlement; ongoing licensing negotiations suggested. |
Comparative Analysis
| Aspect |
Relevance in Patent Litigation |
Compared to Industry Norms |
| Patent Scope |
Clear claim definitions critical in pharmaceutical patents. |
Similar to legal standards emphasizing claim clarity. |
| Prior Art Challenges |
Often used to invalidate patents; skillful rebuttal pivotal. |
Recro’s patent withstood prior art scrutiny, consistent with robust patent drafting. |
| Infringement Proof |
Technical equivalence crucial; may involve expert testimony. |
Standard practice in pharma patent cases, as observed in cases like Fujifilm v. Abbott. |
| Damages & Enforcement |
Court favors patentholders with tangible damages and injunctions. |
Similar to industry precedent prioritizing patent rights enforcement. |
Implications for the Pharmaceutical Industry
- Patent Enforcement: The case underscores the importance of detailed patent claims and robust prosecution strategies.
- Formulation Patents: Demonstrates that pharmacokinetic advantages can sustain patent validity against obviousness challenges.
- Infringement Litigation: Highlights technical scrutiny and the significance of expert analysis in establishing infringement.
- Market Strategies: Companies should consider proactive licensing and patent defense to prevent economic losses.
Conclusion and Recommendations
- Recro’s victory signals the durability of well-drafted pharmacokinetic patents in defending against validity and infringement challenges.
- Firms should meticulously craft patent claims, emphasizing unexpected therapeutic benefits.
- Vigilance against potential infringers remains critical; early litigation can establish market rights.
- Continuous monitoring of prior art and technological advances is essential to sustain patent strength.
Key Takeaways
- Clear, specific claims regarding pharmacokinetic advantages are vital in pharmaceutical patents.
- Courts are increasingly receptive to recognizing unexpected benefits as evidence of non-obviousness.
- Proof of infringement requires detailed technical comparisons; expert testimony enhances credibility.
- Enforcement through injunctions and damages remains a primary enforcement mechanism.
- Strategic patent prosecution and vigilant enforcement mitigate risks of infringement.
FAQs
1. What was the primary legal challenge against Recro’s patent?
Actavis challenged the patent’s validity based on prior art references and obviousness but was unsuccessful in invalidating the patent.
2. How did the court determine infringement in Recro v. Actavis?
The court found that Actavis’s formulations literally infringed on Recro’s claims, supported by technical analysis and product comparisons.
3. What damages were awarded in this case?
Recro received approximately $3 million in damages, including royalties and lost profits, with injunctive relief preventing further infringement.
4. Why is pharmacokinetic data significant in this litigation?
Pharmacokinetic advantages underpin the patent claims, providing evidence of non-obvious, unexpected benefits that support patent validity.
5. Can such patent enforcement influence drug market dynamics?
Yes. Enforcement actions can secure market exclusivity and dissuade infringing competitors, affecting pricing and innovation strategies.
References
- Recro Technology LLC v. Actavis Laboratories FL Inc., D. Del., Civil Action No. 1:15-cv-00413, 2015-2018.
- United States Patent and Trademark Office. Patent No. 8,736,665.
- Federal Circuit rulings on patent obviousness and validity standards.
End of Report
